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Background: Commelina benghalensis (CB) is a small plant whose fleshy stems are used in South Africa to treat skin
conditions (e.g., cancerous skin outgrowths). This study was aimed at evaluating the effect of sub-fractions of
acetone extracts of CB stems on growth-associated molecular events of apoptosis and cell division cycle of Jurkat-T
(JT) cells.
Methods: Acetone extract of CB stems were subfractioned into n-hexane (F1) and dichloromethane (F2) fractions.
After treatment of JT cells with these subfractions, cell proliferation, viability and apoptosis were determined using a
haemocytometer, the trypan blue dye exclusion assay, and Hoechst 33258 staining, respectively. Cell division cycle
distribution profiles were analysed using an Epics Alba Flow Cytometer and the expression of cell division cycle
regulatory genes was analysed using RT-PCR, while immunoreactive proteins were detected on western blots.
Results: The F1 and F2 fractions inhibited the proliferation and viability of JT cells in a concentration- and
time-dependent manner, with IC50 values of 32.5 μg/mℓ and 56 μg/mℓ, respectively. The observed cytotoxicity
was established to be a consequence of apoptosis. as verified using Hoechst staining method. Both fractions
induced a G1/S interphase arrest of the cell division cycle of JT cells.
RT-PCR analyses showed an up-regulatory effect by the F1 fraction in the expression of cyclin B1, cdc2 and bax,
with a down-regulatory effect in the expression levels of bcl-2. Fraction F1 also increased the protein expression
levels of p53 and its downstream regulators, p21 and Cdc2. However, protein Bax and p21 and p53 transcripts
were undetectable under the same experimental conditions. On the other hand, fraction F2 increased the mRNA
expression levels of bax, bcl-2, cyclin B1 and cdc2. Concomitantly, fraction F2 showed an up-regulation in the
protein expression levels of Cdc2, Bcl-2, Cyclin B1 and p21. Despite the up-regulation in protein expression levels
by fraction F2, there was no observable expression levels of the p53 protein and p21 and p53 mRNAs under
similar experimental conditions.
Conclusion: These findings suggest that the F1 and F2 fractions of CB may provide a valuable lead for the
development of novel and effective anti-neoplastic drug(s).
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Cancer is characterised by uncontrolled growth of cells
that may arise either due to genetic abnormalities or viral
causes. The condition is associated with high morbidity
and mortality [1,2]. Although no effective cure, depending
on the type of cancer, has been developed, the condition
can be managed through the use of radiotherapy and
chemotherapy. Indeed, commercially available chemother-
apeutics were found to induce death in neoplastic cells [3].
However, these synthetic drugs are mostly non-specific
and may be associated with severe side-effects as well as
the development of multi-drug resistance phenotypes. In
view of the related drawbacks of these chemotherapeutics,
the search for new anticancer agents, with a focus on nat-
ural compounds from plants, presents an untapped re-
source base with a huge potential [4]. In fact, plants have
been used for the treatment of various disease conditions
for centuries in different cultures. With the renewed inter-
est in the use of natural products on a global perspective,
formulations derived from natural products with medi-
cinal value may be inexpensive and effective with potential
benefit to developing nations [5], especially when these
natural products have a history of traditional use.
The main characteristic feature of cancer is unchecked
cell growth. As such, understanding the cell division cycle
is of primary importance in cancer research. The cell div-
ision cycle represents a series of tightly controlled events
in which a cell grows in size, duplicates its DNA, segre-
gates its chromatin and divides into two daughter cells [6].
These developmental stages in the cell division cycle have
been extensively studied. In Gap phase 1(G1), the cell mass
increases as the cell prepares to synthesize DNA. This is
followed by the synthesis phase (S) where the cell is char-
acterised by DNA synthesis. In Gap phase 2 (G2), DNA re-
pair and protein synthesis prepare the cell’s division. The
cycle is completed by the mitotic phase (M), in which div-
ision of the cell into two daughter cells (cytokinesis) takes
place [7]. In some cases, growing cells withdraw from the
cell division cycle and enter a resting phase (G0) [8,9].
Hence, to ensure accurate replication of the genome and
cytokinesis, checkpoints to monitor the integrity of the
DNA are placed in the G1/S and G2/M interphases [10].
These have led to the identification of positive regulators
that control cell division cycle [11,12].
When cells are damaged, cell division cycle arrest may
occur in either the G2/M or G1/S interphase to allow
complete DNA repair. Extensively damaged cells are com-
mitted to undergo apoptotic cell death [13]. Apoptosis is
highly regulated and critical for the development and
maintenance of healthy tissues. It plays an important role
in the protective mechanism against carcinogenesis by
eliminating genetically damaged cells, initiated cells or
malignant cells. The induction of apoptosis in the treat-
ment of cancer has been considered a highly desirableprocess, due to its highly ordered nature and complete ab-
sence of inflammatory response [14]. Some characteristics
of an apoptotic cell are cell shrinkage, chromatin conden-
sation, DNA fragmentation, plasma membrane blebbing,
membrane flipping and externalisation of phosphatidyl
serine, the formation of apoptotic bodies and activation of
caspases [15].
Commelina benghalensis L. (CB) is used traditionally as
either a food source for its nutritional value or in trad-
itional medicine. The plant is widely used in traditional
medicine in China and Nigeria [16,17]. In South Africa,
traditional healers use the plant to treat skin outgrowths
that are believed to be cancerous. Studies using crude ex-
tract of CB from our research group have shown that it
possesses anti-neoplastic properties and induces apoptosis
in JT cells [18]. In this study, semi-purified extracts of CB
were evaluated for their potential growth inhibitory effect
and dysregulation of cell division cycle progression of
Jurkat-T cells, using standard biochemical and molecular
biology techniques.
Methods
Preparation of plant material and extraction
Commelina benghalensis stems were collected in
Bushbuckridge, Mpumalanga Province, South Africa, dur-
ing summer in dry ice-containing cooler bags. Collected
plant material was identified by Prof. J.N. Eloff (University
of Pretoria) and voucher specimen number (UL69873) is
deposited in the Larry Leach herbarium of the University
of Limpopo, Republic of South Africa. The stems were
transported within 12 h of harvest and stored at -20°C
until required. The frozen stems were minced in liquid
nitrogen using a blender and extracted for 24 h with ab-
solute acetone (1 g/10 mℓ). The extracted material was
filtered through a Whatman no. 3 filter paper and con-
centrated using a rotary evaporator (Büchi Labortechnik
AG, Switzerland) at 40°C under reduced pressure. The
extract residue was then dissolved in ethanol: water (3:1, v/
v) and further fractionated with 40 mℓ each of n-hexane
and dichloromethane to obtain the F1 and F2 fractions, re-
spectively. The fractions were further concentrated with a
rotary evaporator at 40°C under reduced pressure. Prior to
assaying, the resultant residues were resuspended to an ap-
propriate concentration in 100% dimethylsulfoxide (DMSO).
Cell culture and treatment
Jurkat-T (JT) cells were obtained from American Type
Culture Collection (ATCC, Manassas, VA, USA) and grown
in RPMI-1640 media (Adcock-Ingram) supplemented with
10% foetal bovine serum (FBS) (Adcock-Ingram) and 1%
antibiotic cocktail (penicillin, streptomycin and neomycin,
PSN) (Virbac) in an incubator in a humidified atmosphere
of 95% O2 and 5% CO2 at 37°C. For the treatment of ex-
perimental cultures, the stock solutions of the fractions
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supplemented with 10% FBS (Adcock-Ingram) to a final
concentration of 0 to 40 μg/mℓ (F1) and 0 to 90 μg/mℓ
(F2), respectively. The solutions were filter-sterilised
through a 0.22 μm pre-sterilised GP express plus steritop™
filter (Millipore Corporation) before testing. The DMSO
concentration in all the treated cultures did not exceed
0.1%. Control cells received an equivalent amount of the
highest concentration of DMSO used (0.1%).
Cell proliferation and viability assays
JT cells were cultured in 6-well tissue culture plates at a
density of 1 × 105 cells/mℓ and treated with F1 fraction (0,
10, 32.5 and 40 μg/mℓ) and F2 (0, 30, 56 and 90 μg/mℓ)
for 24, 48 and 72 h at 37°C. Cell proliferation was deter-
mined using a haemocytometer with the aid of an inverted
light microscope (Zeiss, Nikon eclipse Ti). Cell viability
was determined by trypan blue dye exclusion assay. Dead
and viable cells were counted using a haemocytometer.
Viability was expressed as percentage (%) survival per 100
cells counted. DMSO was used as a negative control.
Morphological evaluation of apoptosis
JT cells were grown in 6-well tissue culture plates at a dens-
ity of 1 × 105 cells/mℓ and treated with increasing concen-
trations of the F1 and F2, as above, for 24 h. Cells were
then collected by centrifugation at 277 x g, washed with 1 ×
phosphate buffered saline (PBS), pH 7.4, and stained with
20 μg/mℓ Hoechst 33258 for 15 min. The results were ob-
served and recorded under a fluorescence microscope.
Cell synchronisation and cell cycle analysis
JT cells (8 × 105 cells/mℓ) were arrested at G0/G1 phase by
growing in RPMI-1640 serum-free medium (Adcock-
Ingram) for 24 h and released in RPMI-1640 medium
(Adcock-Ingram) supplemented with 10% FBS (Adcock-
Ingram). The exponentially growing-synchronised JT cells
were treated with varying concentrations of F1 fraction (0,
10, 32.5, 40 μg/mℓ) and F2 fraction (0, 30, 56, 90 μg/mℓ)
for 24, 48 and 72 h. The cells were then centrifuged at
143 x g, fixed with 70% ethanol and stored at -20°C until
required.
The fixed cells were washed twice with 1 × ice-cold PBS
(pH 7.4) (Adcock-Ingram) containing 1% bovine albumin
serum (BSA) (Adcock-Ingram). Cell pellets were resus-
pended in propidium iodide/RNaseA solution (0.05 mg/mℓ
propidium iodide, 40 mM Na+-Citrate, pH 7.6, 1 mg/mℓ
DNase free-RNaseA, 0.1% NP-40) for 30 min in the dark at
37°C. Cell division cycle distribution profiles were analysed
using an Epics Alba Flow Cytometer (Beckman-Coulter,
California, USA). Data from 10 000 cells per sample were
collected and analysed using the cell Fit Analysis program
(Beckman-Coulter).Reverse transcription polymerase chain reaction
(RT-PCR) analysis
Expression of cell division cycle regulatory genes (viz., bcl-2,
bax, p21, cdc2 and cyclin B1) were analysed using the RT-
PCR. Test cultures were treated with F1 and F2 fractions
and harvested at 24, 48 and 72 h. Following exposure, cells
were washed twice with ice-cold PBS (Adcock-Ingram), pH
7.4, and total RNA isolated using the high pure RNA isola-
tion kit (Roche) according to the manufacturer’s instruc-
tions. RNA was quantitated by determining A260 readings,
with an OD of 1 considered equivalent to 40 μg/mℓ of
RNA. The integrity and purity of RNA was evaluated by de-
naturing formaldehyde gel electrophoresis and by determin-
ing the A260/A280 ratio, respectively. cDNA synthesis was
performed using MuLV-RT kit (Perkin-Elmer, Massachusetts,
USA) according to manufacturer’s instructions. PCR
was performed in a reaction mixture consisting of 4 μℓ
cDNA, 1 × PCR buffer with 1.5 mM MgSO4, 0.2 μM
each primers and dNTPs, and 1.25 units of AmpliTaq
DNA polymerase (Perkin–Elmer). The PCR reaction
mixture was amplified for 34 cycles on a Hybaid Omni-
gene thermal cycler, with denaturation at 95°C for 1
min, annealing at 60°C for 1 min (for bax, bcl-2 and
p53) and 58°C (for cyclin B1, cdc2, p21 and β-actin) and
extension at 72°C for 1 min and a final extension cycle
at 72°C for 7 min. Oligonucleotide primer pairs, synthe-





















β-Actin was used as an internal standard. PCR prod-
ucts were analysed on a 1.5% agarose gel containing
0.5 μg/mℓ ethidium bromide, visualised under UV light
and photographed using the SynGene Image Analyser
(Vacutec, RSA).
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After treatment with F1 (0, 30, 56, 90 μg/mℓ) and F2 (0,
10, 32.5, 40 μg/mℓ), JT cells were collected by centrifuga-
tion at 277 × g, washed twice in 1x ice-cold PBS, pH 7.4,
and lysed in 1 mℓ lysis buffer (2 mM Tris–HCl, pH 8.0;
1% Nonidet P-40; 13.7 mM NaCl; 10% glycerol; 1 mM
Na3VO4; 1 mM phenylmethylsulfonyl fluoride; 10 μg/mℓ
aprotinin) for 20 min on ice. Lysates were centrifuged at
19 283 × g at 4°C for 15 min and aliquots of the superna-
tants were then used to determine protein concentration
using bicinchoninic acid assay (Pierce). Aliquots contain-
ing equal amounts of proteins (20-30 μg) were boiled for 3
min in a 2 × sodium dodecyl sulphate (SDS) sample load-
ing buffer [125 mM Tris–HCl, pH 6.8; 4% SDS (w/v); 20%
glycerol (v/v); 1 μℓ 2-mercaptoethanol (v/v)] before being
resolved on a 12% SDS-polyacrylamide gel (SDS-PAGE).
The resolved proteins were electro-blotted onto PVDF-
transfer membrane (Millipore Corporation,) using a blot-
ting buffer (10% methanol; 10 mM CAPS, pH 11.0) at 200
mA for 2 h at 4°C. The membranes were blocked with
0.05% TBS-Tween (20 mM Tris–HCl, pH 7.4; 200 mM
NaCl) containing 5% non-fat dry milk for 1 h at room
temperature. The blocked membranes were washed three
times for 10 min with 0.05% TBS-Tween (without milk)
and then incubated with specific primary monoclonal/
polyclonal antibodies (1:1000) as indicated, viz.: goat anti-
mouse p21, goat anti-mouse p53, goat anti-mouse Bcl-2,
goat anti-mouse Cdc2, goat anti-mouse Cyclin B1, goat
anti-mouse β-actin and goat anti-mouse Bax (1:500). The
membranes were washed three times with 0.05% TBS-
Tween for 10 min and further incubated for 1 h in the
presence of a peroxidase-conjugated goat IgG secondary
antibody diluted (1:20 000) with blocking buffer. The
membranes were washed as described above and immu-
noreactive proteins detected using the western blotting
luminol reagent (Santa–Cruz Biotechnology Inc.) follow-
ing the manufacturer’s protocol. β-Actin was used as the
internal control.
Statistical analysis
The results of each series of experiments, where appro-
priate, are expressed as the mean values ± standard error
of the mean (SEM). Levels of statistical significance were
calculated using the paired student t-test when compar-
ing two groups or by analysis of variance (ANOVA) with
subsequent Tukey-Kramer multiple comparisons test for
multiple groups. P values of ≤ 0.05 were considered sta-
tistically significant.
Results and discussions
Developing novel cancer chemotherapeutic agents that
have a well-defined mechanism of action is still an emer-
ging field of oncology. In this direction, plants are being
thoroughly investigated as a source of novel moleculesthat can limit cancer growth [3]. Previous studies from
our laboratory showed that the crude extract of C. ben-
ghalensis possesses anti-proliferative effects and induces
apoptosis in JT cells [18]. In this study we investigated
the effect of semi-purified extracts of C. benghalensis on
growth-associated molecular events of apoptosis and cell
division cycle of JT cells.Effects of the F1 and F2 on JT cell proliferation
and viability
To investigate the effects of the F1 and F2 fractions on cell
proliferation, JT cells were treated with different concen-
trations of both fractions for 24, 48 and 72 h. Both the F1
and F2 fractions inhibited the proliferation of cells in a
time- and concentration-dependent manner (Figures 1A
and B). Cells were incubated for 24, 48 and 72 h in the
presence or absence of different concentrations of the F1
and F2 fractions and the cell numbers were determined
using a haemocytometer. The results are presented as the
mean ± SEM of two independent experiments, each per-
formed in duplicate. The final concentration of DMSO
used in all the treated cells was less than 0.1%.
At 24 h of incubation with the F1 fraction, a marked
variation was not observed between the various concen-
trations used, even at the highest concentration of 40
μg/mℓ. With prolonged extended time of incubation, an
increase in cell proliferation was observed at lower con-
centrations with a concomitant anti-proliferative effect
at the highest concentrations of 30 - 40 μg/mℓ. A similar
trend was observed with the F2 fraction, suggesting that
the anti-proliferative effect of both fractions was evident
only at higher concentrations with extended time of ex-
posure. A measure of the antagonist drug potency (IC50)
in both fractions was determined (Figures 2A and B).
Given that the different concentrations of the two frac-
tions were used in the study, the trend in cell viability
decreased with increase in the concentration of the F1
and F2 fractions (Figures 3A and B).
Both F1 and F2 fractions displayed potent anti-
proliferative activity, with IC50 for F1 fraction at 32.5
μg/mℓ, and 56 μg/mℓ for F2 fraction. The Monkey
Vero cells were used as normal cells to determine the
cytotoxicity of both fractions used. Concentrations of
up to 250 μg/mℓ of either fraction had no inhibitory ef-
fect on these cells (data not shown). The strong growth
inhibitory activity of both fractions prompted us to de-
termine their possible mode of molecular mechanism
(s) of action. Since JT cells are irreversibly transformed,
they have a way of evading apoptosis. Hence, the main
target of any putative and novel bioactive compound
isolated from medicinal plants would be to trigger
apoptosis in these neoplastic cells, while inhibiting
their proliferation.
Figure 1 The anti-proliferative effects of fractions on Jurkat-T cells. The cells were incubated for 24, 48 and 72 hours with A. F1 and B. F2
fractions. Control = cells, Negative control =DMSO, *Statistically significant, p≤0.005. **Statistically significant, p≤0.001.
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JT cells
To further investigate whether the death of the JT cells
was due to the process of apoptosis, and not necrosis,
the morphological changes indicative of the apoptotic
process were assessed. Morphological changes in the
nuclear chromatin during apoptosis can be detected by
Hoechst 33258 staining. In this assay, apoptotic cells are
identified by bright blue nucleus as the chromatin is
condensed, while nuclei of non-apoptotic cells stain a
weak and homogenous blue colour due to the evenly
spread and monogranulated chromatin. After treating
the cells with F1 and F2 fractions for 24 h, the blue
emission light, indicative of apoptosis, in apoptotic cells
was brighter than in the control cells. Condensed chro-
matin was also observed in a large number of fractions
F1- and F2-treated cells with the presence of apoptotic
bodies evident in some cells (Figure 4).Effects of F1 and F2 fractions on cell division cycle
progression of JT cells
The effects of F1 and F2 fractions on the cell division
cycle distribution profiles were assessed by flow cytome-
try. After 24, 48 and 72 h of treatment, 40 μg/mℓ of frac-
tion F1 was observed to gradually increase the S phase
population (Table 1 and Figure 5A) from 29.28% at 24 h
to 41.53% at 72 h, suggesting an increase in S phase
population with prolonged exposure. This increase was ac-
companied by a concomitant decrease in the number of
cells in the G0/G1 phase (66.73% at 24 h, 63.33% at 48 h,
41.75% at 72 h) with prolonged exposure time.
Similarly, fraction F2 was also observed to arrest the cell
division cycle progression at the S phase (Figure 5B). Frac-
tion F2, at 90 μg/mℓ, showed a pronounced increased in
the S phase population from 29.35% at 24 h to 47.80% at
72 h (Table 2). This was accompanied by a sharp decline
of G0/G1 phase cell population from 62.03% at 24 h,
Figure 2 IC50 value of the treated Jurkat-T cells. The cells were incubated for 24, 48 and 72 hours in the presence and absence of different
concentrations of the A. F1 and B. F2 fractions.
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suggesting that both fractions F1 and F2 alter the cell div-
ision cycle by arresting JT cells in the S phase.
Effects of the F1 and F2 fractions on the mRNA
expression levels of p21, p53, cyclin B1, and cdc2
The progression of the cell division cycle is largely con-
trolled by cyclins, the regulatory units of CDKs, and CDKIs.
The expression levels of cyclin B1 mRNA increased follow-
ing fraction F1 treatment at 32.5 μg/mℓ and 40 μg/mℓ after
24 and 72 h. The mRNA expression levels of its catalytic
partner, cdc2, were also increased after 48 h following frac-
tion F1 treatment under the same treatment conditions
(Figure 6A). On the other hand, treatment of JT cells with
fraction F2 also resulted in an increase in the expression
levels of cyclin B1mRNA at 24 and 72 h, while cdc2 mRNA
expression levels were only up-regulated at 72 h (Figure 6B),
suggesting a time lag between the two fractions in the up-
regulation of cdc2 mRNA expression levels. Although the
initial events promoted by F1 fraction on JT cells before the
commencement of apoptosis are not well understood, it
may be likely that the F1 fraction may have increased the
expression of certain genes that may subsequently be im-
portant in mediating the early-response initiation of apop-
tosis, which was not the case with the F2 fraction. However,
p53 mRNA and its downstream regulator, p21 mRNA, for
both F1 and F2-treated JT cells did not display anydetectable levels possibly due to their unstable nature and
short half-lives (data not shown).
Indeed, mRNA degradation is said to be a tightly regu-
lated process dependent on specific cis- and trans-acting
factor interactions [21]. Many mRNAs that are subjected
to message turnover bear AU-rich elements (AREs) in
their 3′-untranslated regions (3′ UTRs), which often con-
tain the pentamer AUUUA [22]. To investigate why frac-
tions F1- and F2-treated cells did not show any detectable
levels of both p21 and p53 mRNAs in the RT-PCR ana-
lysis, the time points in a subsequent experiment were ad-
justed (i.e., 6, 12, 24 and 48 h). Despite these adjustments,
we could still not detect any appreciable expression levels
of p21 and p53 mRNAs. This finding may suggest that the
mRNA transcripts for both genes may have been possibly
degraded.
Effects of the F1 and F2 fractions on the mRNA
expression levels of bax and bcl-2
In the group of genes associated with apoptosis, the bcl-2
family is one of the most important groups due to its regu-
latory role during apoptosis. Among this family of genes,
bcl-2 is anti-apoptotic, whereas bax is known as the pro-
apoptotic gene. The treatment of the JT cells with F1 frac-
tion resulted in a decrease in the bcl-2 mRNA expression
levels in a time- and concentration-dependent manner,
followed by a simultaneous increase in the bax mRNA
Figure 3 Effects of the fractions on the viability of Jurkat-T cells. The cells were incubated for 24, 48 and 72 hours in the presence and
absence of different concentrations of the A. F1 and B. F2 fractions.
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pression levels was more prominent at 48 and 72 h after
treatment with 32.5 μg/mℓ and 40 μg/mℓ, whereas the in-
crease in the bax expression levels was observed at all-time
points tested (24-72 h) (Figure 6A). In view of the fact that
bax genes code for proteins that affect the susceptibility of
cells to undergo apoptosis, it may be likely that the amount
of Bcl-2 and Bax proteins in JT cell vary coordinately or
that the effect of F1 fraction may have influenced a drop in
Bcl-2 levels before the onset of apoptosis.
The expression levels of bcl-2 mRNA and bax mRNA
in JT cells treated with F2 fraction were also investigated.
Expression of bcl-2 mRNA slightly increased at 24 h at
56 μg/mℓ and 90 μg/mℓ (Figure 6B). The expression of
bax mRNA was up-regulation at 48 h after exposure to
F2 fraction at 56 μg/mℓ and 90 μg/mℓ. At 72 h, however,
fraction F2 treatment decreased bax mRNA expression.
Effects of F1 and F2 fractions on the protein levels of Bax
and Bcl-2
Western blot analyses of JT cells demonstrated a
down-modulation of the expression level of Bcl-2 in the
presence of F1 fraction at 32.5 μg/mℓ and 40 μg/mℓ
after 72 h (Figure 7). The expression levels of bcl-2
mRNA in fraction F2-treated JT cells were significantlydown-modulated at all the time points tested (24-72 h)
(Figure 6B). On the other hand, Western blot analysis
of Bax protein of fractions F1- and F2-treated JT cells
did not display any detectable levels (data not shown).
The observed phenomenon may likely be due to the
fact that the Bax protein may have been subjected to
proteasome-mediated degradation under the experi-
mental conditions used.
The western blot analysis of p53 in the fraction F2-
treated JT cells did not exhibit any detectable levels. The
p53 protein has been found to have a short half-life due to
the intricate regulation processes that it has to undergo, in-
cluding reversible cycles of post-translational modification
such as phosphorylation, acetylation and ubiquitination
[23]. Under normal conditions, the p53 tumour suppressor
protein has been considered to be rapidly degraded by the
26S proteasome in a process mediated by the Mdm2 pro-
tein and Jun kinase [24]. Since this study did not demon-
strate any detectable levels of p53, at all the time points
tested, the possibility that the p53 protein could have
undergone proteasomal degradation cannot be ruled out.
However, despite the fact that p53 levels were not detected
under the current experimental conditions, p21Waf1/Cip1
protein levels were highly up-regulated and cell cycle arrest
was induced in the G1/S interphase and with cells
Figure 4 Inhibition of cell cycle progression in Jurkat-T cells after treatment. The cells were incubated with or without the F1 fraction for
24, 48 and 72 hours. Cells were fixed with 70% ethanol, stained with propidium iodide and then the cell cycle distribution was analyzed. The cells
were released from synchronization prior to treatment with the A. F1 fraction. A = serum starved cells for 24 hours, B = control cells, C = cells
treated with F1 fraction at 10 μg/mℓ, D = cells treated with F1 fraction at 32.5 μg/mℓ, E = cells treated with F1 fraction at 40 μg/mℓ. B. F2
fraction. A = serum starved cells for 24 hours, B = control cells, C = cells treated with F2 fraction at 30 μg/mℓ, D = cells treated with F2 fraction at
56 μg/mℓ, E = cells treated with F2 fraction at 90 μg/mℓ. Note the distinct accumulation of cells in the S phase. These results are representative
profiles of the cell division cycle at 72 hours.
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addition to induction of cell cycle arrest in the G1/S
interphase, can induce apoptosis in these cells. The
induction of apoptosis by p21Waf1/Cip1 was not
found to be extensive as compared to that induced by
p53, but it was nonetheless still detectable. These re-
sults suggested that p21Waf1/Cip1 induces apoptosis in a
p53-independent manner in the fraction F2-treated
JT cells. This also suggests that the up-regulation
of p21Waf1/Cip1 may be related to fraction F2-
induced G1/S interphase block and growth inhibition
in JT-cells.
Since our results demonstrated an up-regulation in
the protein expression levels of p21Waf1/Cip1, which
led to the arrest of cell cycle in the G1/S interphase, it
was essential to investigate its effects on the cell div-
ision cycle regulatory proteins operative within the
G1/S interphase, including Cyclin B1 and Cdc2. The
products of these cell division cycle regulatory genes
are critical determinants of the progression of cancer.
Their dysregulation is considered to have an adverse ef-
fect on the normal cycling of cells [25].Table 1 Cell cycle distribution profiles of Jurkat-T cells treate
Cell cycle phase Time (hours) 0 μg/mℓ
G0/G1 24 65.95% ± 6.70
48 64.50% ± 3.46
72 58.00% ± 1.31
S 24 28.73% ± 5.42
48 28.28% ± 4.38
72 38.53% ± 4.58
G2/M 24 7.28% ± 1.23
48 11.00% ±1.18
72 9.08% ± 3.88Consequently, RT-PCR analysis of fraction F1-treated JT
cells revealed an up-regulation in the expression levels of
cyclin B1 mRNA at 24 and 72 h and an up-regulation of its
catalytic partner, cdc2 mRNA, after 48 h at concentrations
of 56 and 90 μg/mℓ. Western blot analysis of the fraction
F1-treated JT cells demonstrated an up-regulation in the
expression levels of the Cdc2 protein after 48 h at concen-
trations of 56 and 90 μg/mℓ. Further, RT-PCR analysis of
the fraction F2-treated JT cells resulted in an up-regulation
in the expression levels of cyclin B1 mRNA at 24 and 72 h,
whereas the expression levels of its catalytic partner, cdc2,
were up-regulated after 72 h. Contrary to the cdc2 mRNA
RT-PCR data, the Cdc2 protein was up-regulated at all the
time points tested (24, 48 and 72 h). Indeed, an up-
regulation in the expression levels of the Cdc2 protein is
considered to be a common feature among apoptosis in-
duced by any form of stimuli without an effect on the cell
division cycle progression [26]. Our findings, therefore, sug-
gest that the up-regulation in the expression levels of Cdc2
protein after treatment with fractions F1 and F2 could have
possibly led to the induction of apoptosis independent of
the G1/S interphase arrest.d with different concentrations of the F1 fraction
10 μg/mℓ 32.5 μg/mℓ 40 μg/mℓ
63.95% ± 1.55 68.65% ± 6.00 66.73% ± 2.08
62.25% ± 0.05 62.00% ± 0.25 63.33% ± 0.68
60.03% ± 1.63 51.88% ± 8.43 41.75% ± 2.03
31.20% ± 0.65 28.33% ± 3.83 29.28% ± 0.48
33.58% ± 2.03 32.30% ± 3.65 27.65% ± 2.30
36.08% ± 0.43 38.70% ± 2.35 41.53% ± 3.08
7.73% ± 0.28 7.48% ± 0.28 5.88% ± 3.33
9.03% ± 2.98 9.13% ± 2.98 12.28% ± 0.83
6.30% ± 5.58 13.68% ± 5.58 4.95% ± 0.00
AB
Figure 5 Effects of the fractions on mRNA expression of bax, bcl-2, cdc2 and cyclin B1 in Jurkat-T cells. A. F1 fraction; lane 1 = control;
lane 2 = 10 μg/ml; lane 3 = 32.5 μg/mℓ and lane 4 = 40 μg/mℓ. B. F2 fraction; lane 1 = control; lane 2 = 30 μg/mℓ; lane 3 = 56 μg/mℓ and lane 4 = 90
μg/mℓ. Total RNA was prepared and RT-PCR performed as described in the materials and methods. β-actin was used as the internal control.
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http://www.biomedcentral.com/1472-6882/14/65Western blot analysis of Cyclin B1 of the fractions F1-
and F2-treated cells also did not show any detectable
levels. This could have possibly been due to the fact that
Cyclin B1 protein may have been subjected to a protea-
somal degradation process. This is so because intracellu-
lar protein degradation plays an essential role in many
physiological processes by removing damaged proteins
that harbour destruction (ubiquitin) tags. In eukaryotic
cells, degradation of cytosolic and nuclear proteins is
mainly mediated by the 26S proteasome [27].The key biochemical events involved in the induction of
apoptosis are the up-regulation of pro-apoptotic proteins
and/or down-regulation of anti-apoptotic proteins. There-
fore, the ratio of pro-apoptotic to anti-apoptotic proteins
of the Bcl-2 family is an important determinant of a cell’s
bias to undergo apoptosis. The Bcl-2 family of proteins
either promotes cell survival (e.g., Bcl-2) or induces apop-
tosis (e.g., Bax). Increased levels of Bax and concomitant
decreased levels of Bcl-2 have been suggested to perme-
abilise the mitochondria to release pro-apoptotic factors
Table 2 Cell cycle distribution profiles of Jurkat-T cells treated with different concentrations of the F2 fraction
Cell cycle phase Time (hours) 0 μg/mℓ 30 μg/mℓ 56 μg/mℓ 90 μg/mℓ
G0/G1 24 69.68% ± 1.18 69.35% ± 2.10 67.13% ± 3.88 62.03% ± 0.93
48 61.13% ± 4.23 61.08% ± 1.28 51.65% ± 0.8 58.50% ± 2.95
72 64.83% ± 11.23 61.30% ± 3.80 55.30% ± 0.2 44.35% ± 7.80
S 24 23.63% ± 0.93 26.28% ± 2.28 24.45% ± 3.45 29.35% ± 3.25
48 29.15% ± 2.70 29.53% ± 1.18 37.68% ± 0.88 29.88% ± 0.18
72 29.23% ± 5.68 36.90% ± 7.95 39.45% ± 5.5 47.80% ± 0.50
G2/M 24 9.08% ± 0.63 8.03% ± 1.68 12.40% ± 2.05 11.40% ± 1.80
48 12.00% ± 1.45 11.35% ± 2.3 12.50% ± 0.15 13.93% ± 3.43
72 6.65% ± 0.00 5.50% ± 0.00 6.65% ± 0.00 11.85% ± 5.10
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activation [13]. Subsequently, the present study demon-
strated a time- and concentration-dependent decrease in
the expression levels of bcl-2 mRNA and increased levels
of bax mRNA in the fraction F1-treated JT cells. On the
other hand, there was a down-modulation of the Bcl-2 pro-
tein after 72 h treatment with F2 fraction, at concentrationFigure 6 Effects of the F1 fraction on the expression levels of p53, p2
μg/mℓ; lane 3 = 32.5 μg/mℓ; lane 4 = 40 μg/mℓ. Total cellular proteins we
and methods. Note the kinetics of p21 up-regulation which coincided with
β-actin was used as the internal control.of 32.5 and 40 μg/mℓ. Furthermore, treatment of cells with
fraction F2 resulted in an up-regulation in the expression
levels of bax mRNA at 48 h and bcl-2 mRNA after 24 h,
both at concentrations of 56 and 90 μg/mℓ.
Since biological processes are normally driven by pro-
teins, immunoblot analysis was done in order to confirm
the RT-PCR results. The Western blot results for fraction1, Bcl-2 and Cdc2 in Jurkat-T cells. Lane 1 = control; lane 2 = 10
re prepared and western blot performed as described in the materials
the up-regulation of p53.
Figure 7 Morphological changes of the nuclei of treated Jurkat-
T cells. Cells were treated with 0.09% DMSO (A), 40 μg/mℓ of F1 (B)
and 90 μg/mℓ of F2 (C) fraction and stained with Hoechst 33258
stain after 24 hours. Note the presence of apoptotic features such as
nuclear shrinkage and chromatin condensation are prominent in B
and C. The experiment was repeated twice to
ascertain reproducibility.
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http://www.biomedcentral.com/1472-6882/14/65F2-treated JT cells did not corroborate the observations
made from the RT-PCR data. There was a time- and
concentration-dependent decrease in the expression levels
of Bcl-2 protein in fraction F2-treated cells. Several rea-
sons pertaining to this discrepancy can be suggested. This
inconsistency could be a consequence of differences in
post-translational regulatory mechanisms, as well as differ-
ences in mRNA and protein turnover [28].
Western blot analysis of the Bax protein, for fractions F1-
and F2-treated cells, did not show any detectable levels. It
has been shown previously that certain apoptosis-promoting
proteins such as Bax are subjected to proteasome-mediated
degradation [29]. It also has been suggested that Bax, as
compared to Bcl-2, is a direct target protein of the ubiquitin/
proteasome pathway [30]. p53 induces apoptosis through the
induction of Bax. Thus, the ubiquitin-proteasome may nega-
tively regulate p53-dependent apoptosis by degrading the
p53 downstream target, the Bax protein [23].
The time points that were used for the Western blot
analyses (24, 48 and 72 h) seemed not to have been ideal
for the detection of the Bax protein in fractions F1- and
F2-treated JT cells. This observation may suggest that the
Bax protein messages could have been translated within
24 h and as such could not be possibly detected beyond
this time point. Consequently, another experiment with
earlier sampling time-point intervals (6 and 12 h) was con-
ducted, but could still not detect any expression levels of
Bax protein. Therefore, we speculate that the Bax protein
could have undergone ubiquitin proteasomal degradation.
Despite the non-detection of the Bax protein, the treated
cells did undergo apoptosis as evidenced by the down-
regulation of the anti-apoptotic protein Bcl-2. This findingcould, indeed, explain the disproportionate expression
profiles of both p53 and Bax proteins observed in the
present study.
The above information could buttress the idea that JT
cells, under the conditions of fraction F1 and F2 treat-
ment, undergo apoptosis independent of the Bax protein.
It also shows that p53 repressed the expression of Bcl-2 in
the fraction F1-treated JT cells and thereby contributed to
apoptosis by blocking survival signals mediated by Bcl-2.
The data also suggested that the down-modulation of Bcl-2
in fraction F2-treated JT cells might be another molecular
mechanism through which fraction F2 induces apoptosis;
however, this explanation needs to be explored.
Our findings also suggest that fraction F1 inflicted an in-
sult to the JT cells, thus leading to the activation of the
tumour suppressor protein, p53. p53 in turn up-regulated
the expression levels of p21Waf1/Cip1, thus leading to the
arrest of cells in the G1/S interphase. The resultant G1/S
interphase arrest meant that the cells were given enough
time for DNA repair. However, since the damage was irrep-
arable, the p53 promoted apoptosis by down-regulating the
expression levels of Bcl-2 and the damaged JTcells were then
eliminated. In the case of the fraction F2-treated JT cells, we
suggest that p21waf1/Cip1 played a dual role of arresting
and inducing apoptosis in the JT cells. Fraction F2-treated JT
cells also induced cell cycle arrest in the G1/S interphase,
with cells consequently undergoing apoptosis through the
down-modulation of the expression levels of Bcl-2 protein.
Conclusion
Results from the current study showed that the F1 and F2
fractions exhibit remarkable growth inhibitory effects against
JT cells. The study also demonstrated that JT cells treated with
different concentrations of F1 and F2 fractions display some of
the classical morphological hallmark features of apoptosis,
such as cell shrinkage, chromatin condensation, DNA frag-
mentation and plasma membrane blebbing. Fraction F1-
treated JT cells also demonstrated increased expression levels
of p21Waf1/Cip1 and p53 and a simultaneous arrest of the
cell division cycle in the G1/S interphase. This finding suggests
that the induction of p21Waf1/Cip1 is p53-dependent and
that p21Waf1/Cip1 plays a role in fraction F1-induced G1/S
arrest of treated JTcells.
Fraction F1 is also shown to inhibit cell proliferation ac-
companied by the up-regulation of p53, p21Waf1/Cip1 and
Cdc2, while fraction F2 inhibits cell proliferation via the
up-regulation of p21Waf1/Cip1 and Cdc2. It is thus likely
that both fractions induce apoptosis through a down-
regulation of Bcl-2 in JTcells. However more studies are re-
quired to buttress this assumption. Hence, fractions F1 and
F2 of CB may have anti-tumour effects which are mediated
through the G1/S interphase arrest. Furthermore, these re-
sults suggest that CB may have a potential to be developed
as a therapeutic agent against cancer. Although the study
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http://www.biomedcentral.com/1472-6882/14/65presents preliminary data, the results somewhat validate
the ethnopharmacological usage of this plant in the
treatment of malignant phenotypes. Future studies will
focus on the understanding of the actual mechanism(s)
of action that is (are) associated with the observed cell
death events. Chemical structure elucidation of the
bioactive compounds, that are present in and are re-
sponsible for the observed activity elicited by fractions
F1 and F2, is also pertinent.
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